Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Gupta A, Rudra A, Reed K, Langer R, Anderson DG
Vaccines play a critical role in the prevention of life-threatening infectious disease. However, the development of effective vaccines against many immune-evading pathogens such as HIV has proven challenging, and existing vaccines against some diseases such as tuberculosis and ma…
Kim H, Shin SJ
Mycobacterium kansasii is a bacterium included in non-tuberculous mycobacteria (NTM) that can cause lung disease. It shares a significant number of antigens with Mycobacterium tuberculosis (Mtb), suggesting that it has the potential to be used as a tuberculosis (TB) vaccine. Ther…
Sumner T, Clark RA, Mukandavire C, Portnoy A, Weerasuriya CK, et al.
…d 300,000 cases and 55,000 deaths in 2021. New tuberculosis vaccines could play an important role in reducing this burden. Phase IIb trials have suggested efficacy of the M72/AS01 E vaccine candidate and BCG-revaccination. The potential population impact of these vaccines is unkn…
Isaquel Silva, Sebastian Nielsen, Peter Aaby, Christine Stabell Benn, Frederik Schaltz-Buchholzer
**BACKGROUND:** Within a randomised controlled trial providing Bacillus Calmette-Guérin, measles vaccine, or placebo to women of fertile age, we aimed to study the risk of adverse events following vaccination. This study addresses the lack of data on adverse reactions in adu…
Méndez-Samperio P
…fers variable protective efficacy in adults. Therefore, new vaccines against TB are needed to overcome this serious disease. At present, around 14 TB vaccine candidates are in different phases of clinical trials. These TB vaccines in clinical evaluation can be classified into two…
Ramon A Juste, Iker A Sevilla, Esmeralda Minguijon, Miguel Fuertes, Natalia Elguezabal, et al.
…arative efficacy of homologous and heterologous inactivated vaccines against that of the live Bacille Calmette-Guérin (BCG) vaccine on M. bovis isolation, gross TB lesions, and immune responses. Data from four controlled vaccination and challenge trials involving 41 calves w…
Blanco FC, Vázquez CL, García EA, Rocha RV, Klepp LI, et al.
A vaccine for bovine tuberculosis is urgently needed. The BCG vaccine (the Bacille Calmette-Guérin), currently the only licensed vaccine for tuberculosis in humans, offers variable protection in cattle. However, BCG is a highly safe vaccine, and any alternative vaccine must not o…
Yun JS, Kim AR, Kim SM, Shin E, Ha SJ, et al.
… to only children, the development of new tuberculosis (TB) vaccines is being studied using several platforms, and a novel TB vaccine that overcomes this limitation is required. In this study, we designed an effective multi-epitope vaccine against Mycobacterium tuberculosis using…
Thysen SM, Byberg S, Martins JSD, Kallestrup P, Griffiths UK, et al.
In Guinea-Bissau, a vial of BCG vaccine is often not opened unless 10 infants are present for vaccination, with the aim of reducing vaccine wastage. This causes delays in vaccination, as previously demonstrated in Guinea-Bissau and other low-income countries. Reducing wastage of …
Zhang D, Zhao H, Li P, Wu X, Liang Y
Traditional vaccines have played an important role in the prevention and treatment of infectious diseases, but they still have problems such as low immunogenicity, poor stability, and difficulty in inducing lasting immune responses. In recent years, the nucleic acid vaccine has e…
Gopalaswamy R, Subbian S
…d conditions, such as HIV infection, is questionable. Novel vaccines, including recombinant BCG (rBCG), were developed to improve BCG's efficacy and use as an alternative to BCG in a vulnerable population. The first-generation rBCG vaccines had different Mtb antigens and were tes…
Jong RM, Van Dis E, Berry SB, Nguyenla X, Baltodano A, et al.
…nually than any other single pathogen, making new effective vaccines an urgent priority for global public health. Among potential adjuvants, STING-activating cyclic dinucleotides (CDNs) uniquely stimulate a cytosolic sensing pathway activated only by pathogens. Recently, we demon…
Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, et al.
Background A therapeutic vaccine that prevents recurrent tuberculosis would be a major advance in the development of shorter treatment regimens. We aimed to assess the safety and immunogenicity of the ID93 + GLA-SE vaccine at various doses and injection schedules in patients with…
Ashhurst AS, Parumasivam T, Chan JGY, Lin LCW, Flórido M, et al.
…ategy has highlighted the urgent need for more effective TB vaccines to improve control of the disease. Protein-based subunit vaccines offer potential as safe and effective generators of protective immunity, and the use of particulate vaccine formulation and delivery by the pulmo…
Stensballe LG, Ravn H, Birk NM, Kjærgaard J, Nissen TN, et al.
Background The bacillus Calmette-Guérin (BCG) vaccine against tuberculosis might reduce the non-tuberculosis-related child mortality rate in low-income settings. We tested the hypothesis that BCG vaccination at birth would reduce early childhood hospitalization for infection in D…
Festjens N, Vandewalle K, Houthuys E, Plets E, Vanderschaeghe D, et al.
…eria could be instructive also for other live attenuated TB vaccines that are currently under development, and encourage further studies of SapM mutation as a strategy in developing a more protective live attenuated TB vaccine.
Hira Tanvir, Rebecca A Clark, Tom Sumner, Katherine C Horton, Tomos O Prŷs-Jones, et al.
…remains a leading cause of infectious disease death. New TB vaccines are currently in late-stage trials and may be available before the end of the decade. Modelling predicts new TB vaccines may reduce global burden but rely on assumptions about vaccine efficacy by TB disease stag…
Zatarain-Barrón ZL, Ramos-Espinosa O, Marquina-Castillo B, Barrios-Payán J, Cornejo-Granados F, et al.
The global control of Tuberculosis remains elusive, and Bacillus Calmette-Guérin (BCG) -the most widely used vaccine in history-has proven insufficient for reversing this epidemic. Several authors have suggested that the mass presence of vaccinated hosts might have affected the M…
Sweeney E, Dahly D, Seddiq N, Corcoran G, Horgan M, et al.
Background Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single infectious agent. Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for TB, yet its efficacy remains debated with variations in vaccine sub-strains, policies, …
Divens AM, Ma L, Vance JK, Povroznik JM, Hu G, et al.
Tuberculosis (TB) is a serious public health concern in many regions of the world and the only approved vaccine to prevent TB is the live-attenuated BCG vaccine. Despite being widely used, the BCG vaccine fails to prevent pulmonary TB in adults. The BCG vaccine is administered du…
Kim C, Holm M, Frost I, Hasso-Agopsowicz M, Abbas K
…avertable bacterial AMR burden based on existing and future vaccines at the regional and global levels by pathogen and infectious syndromes. Methods We developed a static proportional impact model to estimate the vaccination impact on 15 bacterial pathogens in terms of reduction …
Srivastava S, Dey S, Mukhopadhyay S
…nd impacted by the inefficacy of drugs, absence of advanced vaccines, misdiagnosis improper treatment, and social stigma. The BCG vaccine provides partial effectiveness in demographically distinct populations and the prevalence of multidrug-resistant (MDR) and extensively drug-re…
Van Tilbeurgh M, Lemdani K, Beignon AS, Chapon C, Tchitchek N, et al.
Vaccines represent one of the major advances of modern medicine. Despite the many successes of vaccination, continuous efforts to design new vaccines are needed to fight "old" pandemics, such as tuberculosis and malaria, as well as emerging pathogens, such as Zika virus and sever…
Sable SB, Posey JE, Scriba TJ
Tuberculosis (TB) is the leading killer among all infectious diseases worldwide despite extensive use of the Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine. A safer and more effective vaccine than BCG is urgently required. More than a dozen TB vaccine candidates are un…
Ouh IO, Kim MJ, Kim K, Lim H, Yang YJ, et al.
…the development of safer, more effective, and accessible TB vaccines.